Nephrotic Syndrome
📧 Sign up to get email alerts when something new happens for Nephrotic Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-09-16Clinical Trial Update: Diuretic Tuner Clinical Decision Support [NA]
A clinical trial update indicates that a Diuretic Tuner Clinical Decision Support tool is currently recruiting at UT Southwestern Medical Ce…
-
FDA approval · 2025-09-12FDA Approved: ENBUMYST — Original Application (Corstasis USA LLC)
The FDA approves ENBUMYST (bumetanide) from Corstasis USA LLC via its Original Application (NDA219500).
-
CLINICAL_TRIALS research · 2025-09-09Clinical Trial Update: The Role of Proprotein-convertase-subtilisin/Kexin-type 9 in Kidney Damage in Nephrotic Syndrom
This clinical trial update describes an ongoing study evaluating the role of PCSK9 in kidney damage within nephrotic syndrome and notes that…
-
FDA approval · 2025-09-08FDA Approved: FUROSEMIDE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for furosemide from Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc., updating/expandin…
-
CLINICAL_TRIALS trial_result · 2025-09-04Clinical Trial Update: Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria. [Phase 4]
Phase 4 study evaluating the efficacy of usual Vitamin D3 (cholecalciferol) supplementation on calciuria in children and adolescents with ch…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-09-04Clinical Trial Update: Comparing the Performance of Serum Creatinine and Cystatin C-based GFR Estimations in Predicting Directly Measured GFR in Patients With or Without Nephrotic Syndrome
This clinical trial update compares serum creatinine- and cystatin C-based GFR estimations with directly measured GFR in patients with and w…
-
CLINICAL_TRIALS research · 2025-08-29Clinical Trial Update: Study of Therapeutic Efficacy of CAR-T Cell Therapy in Patients With MDR-SRNS [Phase 1]
Phase 1 clinical trial evaluating CAR-T cell therapy for multi-drug resistant nephrotic syndrome, currently recruiting.
-
CLINICAL_TRIALS withdrawal · 2025-08-22Clinical Trial Update: The Biosensor Using the Target Urine VOCs for Detecting DKD Diabetic Kidney Disease
A clinical trial investigating a urine VOC biosensor for detecting diabetic kidney disease and nephrotic syndrome has been withdrawn.
-
CLINICAL_TRIALS research · 2025-08-11Clinical Trial Update: Edoxaban Steady-State PK/PD in Adults With Nephrotic Syndrome [NA]
This clinical trial entry describes a study of steady-state pharmacokinetics and pharmacodynamics of edoxaban in adults with nephrotic syndr…
-
FDA approval · 2025-08-06FDA Approved: FUROSEMIDE — Supplemental Application (Meitheal Pharmaceuticals Inc.)
FDA approved a supplemental application for the generic diuretic furosemide from Meitheal Pharmaceuticals Inc. under ANDA 212803.
-
CLINICAL_TRIALS research · 2025-08-06Clinical Trial Update: Blinatumomab for CNI-Resistant/Intolerant SRNS in Children [Phase 1]
Phase 1 trial evaluating blinatumomab for children with calcineurin inhibitor–resistant or intolerant steroid-resistant nephrotic syndrome; …
-
FDA approval · 2025-07-25FDA Approved: SPIRONOLACTONE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approves Camber Pharmaceuticals' generic spironolactone under an original application (ANDA 217761).
-
FDA approval · 2025-07-17FDA Approved: FUROSEMIDE — Original Application (Aurobindo Pharma Limited)
FDA approves Aurobindo Pharma Limited's original ANDA for furosemide, a generic loop diuretic. The approval covers the generic product for i…
-
CLINICAL_TRIALS research · 2025-07-17Clinical Trial Update: The Selection of Initial Treatment Regimens for Adolescent Nephrotic Syndrome.
This clinical trial update outlines the selection of initial treatment regimens for adolescents with nephrotic syndrome and indicates the st…
-
FDA approval · 2025-06-13FDA Approved: BUMETANIDE — Supplemental Application (Qilu Pharmaceutical Co., Ltd.)
FDA approved a supplemental application for bumetanide from Qilu Pharmaceutical Co., Ltd., authorizing the generic product's approval.
-
CLINICAL_TRIALS research · 2025-06-08Clinical Trial Update: Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
A clinical trial update from Assistance Publique - Hôpitaux de Paris describes a study on epithelial dysmetabolism and renal fibrosis in ANC…
-
FDA approval · 2025-05-08FDA Approved: FUROSEMIDE — Supplemental Application (Eugia US LLC)
FDA approved a supplemental application for furosemide by Eugia US LLC under an ANDA, confirming approval of the supplement.
-
CLINICAL_TRIALS research · 2025-05-07Clinical Trial Update: Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNS [Phase 1]
A Phase 1 clinical trial evaluating anti-CD19 CAR-T cell therapy for multidrug-resistant steroid-resistant nephrotic syndrome is currently r…
-
CLINICAL_TRIALS trial_result · 2025-04-22Clinical Trial Update: Effectiveness of Educational Gamified Cards About Nephrotic Syndrome [NA]
Completed clinical trial evaluating the effectiveness of educational gamified cards for nephrotic syndrome.
-
CLINICAL_TRIALS trial_result · 2025-04-11Clinical Trial Update: Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome [Phase 1, Phase 2]
A completed Phase 1/2 clinical trial from the University of Aarhus explored the causes and prevention of thromboembolic disease in nephrotic…
-
FDA approval · 2025-04-03FDA Approved: BUMETANIDE — Original Application (First Nation Group, LLC)
FDA approves bumetanide under an Original Application filed by First Nation Group, LLC (ANDA219291).
-
FDA approval · 2025-02-27FDA Approved: BUMETANIDE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' original application for bumetanide, a loop diuretic used to treat edema due to congestive heart failur…
-
FDA approval · 2025-02-21FDA Approved: SPIRONOLACTONE — Original Application (Camber Pharmaceuticals, Inc.)
The FDA approved Camber Pharmaceuticals' original application for spironolactone, establishing a generic version of the diuretic. Spironolac…
-
CLINICAL_TRIALS research · 2025-02-11Clinical Trial Update: Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic Syndrome [Phase 3]
Phase 3 clinical study evaluating Rituximab for idiopathic membranous nephropathy with nephrotic syndrome is currently recruiting.
-
CLINICAL_TRIALS research · 2025-01-30Clinical Trial Update: Biomarkers and Outcome Predictors of Pediatric Nephrotic Syndrome: A Genetic, Transcriptomic, and Secretome Multiomics Study
Pediatric nephrotic syndrome study aiming to identify biomarkers and outcome predictors through genetic, transcriptomic, and secretome multi…